Ligand Pharmaceuticals Q1 2026 Earnings Report

Ligand Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: $1.84
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Ligand Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $59.10 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Ligand Pharmaceuticals Announcement Details

• Quarter: Q1 2026
• Date: 5/14/2026
• Time: Before Market Opens
• Conference Call Date: Thursday, May 7, 2026
• Conference Call Time: 8:30AM ET

Ligand Pharmaceuticals (NASDAQ:LGND), Inc. is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms. Captisol® is a chemically modified cyclodextrin used to improve the solubility, stability and delivery of small-molecule drug candidates. Ligand’s research services portfolio includes antibody discovery and optimization through its OmniAb™ platform, as well as absorption, distribution, metabolism and excretion (ADME) testing services provided by its Cyprotex and Absorption Systems subsidiaries. Together, these technologies and services support early- and late-stage drug development programs for a broad range of partners worldwide.

Founded in 1987 and headquartered in San Diego, California, Ligand has grown through strategic acquisitions and collaborations, establishing a global footprint that spans North America, Europe and Asia. The company’s leadership team is led by President and Chief Executive Officer John L. Higgins, whose experience in drug development and corporate transactions has guided Ligand’s transformation into a technology-focused partner for the biopharmaceutical industry. Ligand continues to seek new alliances and in-licensing opportunities aimed at expanding its platform capabilities and royalty revenue streams.